Michal Vrablik Selected Research

Apolipoproteins

1/2003

Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michal Vrablik Research Topics

Disease

9	Atherosclerosis 05/2022 - 01/2011
7	Cardiovascular Diseases (Cardiovascular Disease) 09/2022 - 08/2008
5	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 05/2011
4	Inflammation (Inflammations) 01/2022 - 01/2011
4	Muscular Diseases (Myopathy) 01/2022 - 01/2012
3	Myocardial Infarction 01/2022 - 01/2003
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 05/2013
3	Dyslipidemias (Dyslipidemia) 10/2019 - 01/2011
3	Myalgia 12/2017 - 01/2012
2	Hypertension (High Blood Pressure) 01/2022 - 01/2021
2	Diabetes Mellitus 01/2021 - 05/2013
2	Thromboembolism 01/2008 - 10/2006
1	Rheumatoid Arthritis 09/2022
1	Multiple Sclerosis 06/2022
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2022
1	Heart Failure 01/2022
1	Polymyositis 01/2022
1	Dermatomyositis (Dermatopolymyositis) 01/2022
1	Tachycardia (Tachyarrhythmias) 01/2022
1	Rheumatic Diseases (Rheumatism) 01/2022
1	Vascular Diseases (Vascular Disease) 12/2021
1	Acute Coronary Syndrome 01/2021
1	Virus Diseases (Viral Diseases) 01/2020
1	Infections 01/2020
1	COVID-19 01/2020
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 12/2017
1	Injection Site Reaction 01/2017
1	Unstable Angina 01/2017
1	Stroke (Strokes) 01/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 05/2013
1	Osteoporosis 01/2012
1	Coronary Disease (Coronary Heart Disease) 01/2012
1	Atrophy 01/2012
1	Hypercholesterolemia 01/2011
1	Body Weight (Weight, Body) 01/2011
1	Overweight 01/2011
1	Frailty 01/2011
1	Weight Loss (Weight Reduction) 01/2011

Drug/Important Bio-Agent (IBA)

11	LipidsIBA 09/2022 - 04/2016
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2021 - 01/2011
6	oxidized low density lipoproteinIBA 05/2022 - 04/2016
3	CholesterolIBA 06/2022 - 01/2011
3	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2003
2	LDL CholesterolIBA 05/2022 - 01/2021
2	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2011
2	Fenofibrate (CiL)FDA LinkGeneric 01/2021 - 04/2016
2	EnzymesIBA 12/2017 - 01/2011
2	Atorvastatin (Lipitor)FDA Link 12/2017 - 01/2012
2	coenzyme Q10 (CoQ10)IBA 12/2017 - 01/2012
2	HDL CholesterolIBA 05/2013 - 05/2011
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	Angiotensin Receptor AntagonistsIBA 01/2022
1	Apolipoprotein B-100 (Apo B 100)IBA 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	IncretinsIBA 01/2022
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2022
1	Ligases (Synthetase)IBA 01/2022
1	Proprotein Convertase 9IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022
1	LDL Receptors (LDL Receptor)IBA 01/2022
1	InterleukinsIBA 12/2021
1	Pharmaceutical PreparationsIBA 12/2021
1	canakinumab FDA Link 12/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Simvastatin (Zocor)FDA LinkGeneric 12/2017
1	bococizumabIBA 01/2017
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 06/2015
1	Estrogens (Estrogen)FDA Link 01/2012
1	Apolipoproteins E (ApoE)IBA 01/2011
1	Oxidoreductases (Dehydrogenase)IBA 01/2011
1	glutaryl-coenzyme A (glutaryl-CoA)IBA 01/2011
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2011
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 10/2006
1	ApolipoproteinsIBA 01/2003

Therapy/Procedure

9	Therapeutics 01/2022 - 01/2012
3	Estrogen Replacement Therapy 08/2008 - 10/2006
2	Secondary Prevention 01/2021 - 01/2012
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2012 - 08/2008
1	Cutaneous Administration 10/2006